Evidence map›Paper›PMID 35789908›Full record

ArticleData in brief2022

Monoclonal antibodies binding data for SARS-CoV-2 proteins.

Nawneet Mishra, Joan Teyra, RuthMabel Boytz, Shane Miersch, Trudy N Merritt, Lia Cardarelli, Maryna Gorelik, Filip Mihalic, Per Jemth, Robert A Davey and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nawneet MishraDepartment of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, MO 63110, U.S.A.
Joan TeyraThe Donnelly Centre, University of Toronto, Toronto, Canada.
RuthMabel BoytzDepartment of Microbiology, Boston University School of Medicine, St Louis, MO 63110, U.S.A.
Shane MierschThe Donnelly Centre, University of Toronto, Toronto, Canada.
Trudy N MerrittDepartment of Medicine, Washington University School of Medicine, St Louis, MO 63110, U.S.A.
Lia CardarelliThe Donnelly Centre, University of Toronto, Toronto, Canada.
Maryna GorelikThe Donnelly Centre, University of Toronto, Toronto, Canada.
Filip MihalicDepartment of Medical Biochemistry and Microbiology, Uppsala University, B.M.C. Box 582, Husargatan 3, 751 23 Uppsala Sweden.
Per JemthDepartment of Medical Biochemistry and Microbiology, Uppsala University, B.M.C. Box 582, Husargatan 3, 751 23 Uppsala Sweden.
Robert A DaveyDepartment of Microbiology, Boston University School of Medicine, St Louis, MO 63110, U.S.A.
Sachdev S SidhuThe Donnelly Centre, University of Toronto, Toronto, Canada.
Daisy W LeungDepartment of Medicine, Washington University School of Medicine, St Louis, MO 63110, U.S.A.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, MO 63110, U.S.A.

Funding

Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2R01AI161374 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2021 to 2023
$2.7M
Multi-platform High Throughput Screens for Filoviral Replication InhibitorsR01AI123926 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2016 to 2018
$2.1M
STRUCTURAL BASIS FOR IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINSR01AI107056 · NIAID · WASHINGTON UNIVERSITY · PI LEUNG, DAISY W · 2013 to 2017
$1.9M
NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI107056NIAID NIH HHS R01 AI123926NIAID NIH HHS R01 AI161374
6 · The paper itself

Abstract

SARS-CoV-2 pandemic opens up the curiosity of understanding the coronavirus. This demand for the development of the regent, which can be used for academic and therapeutic applications. The present data provide the biochemical characterization of synthetically developed monoclonal antibodies for the SARS-CoV-2 proteins. The antibodies from phage-displayed antibody libraries were selected with the SARS-CoV-2 proteins immobilized in microwell plates. The clones which bind to the antigen in Fab-phage ELISA were selected, and a two-point competitive phage ELISA was performed. Antibodies binding kinetic of IgGs for SARS-CoV2 proteins further carried with B.L.I. Systematic analysis of binding with different control proteins and purified SARS-CoV-2 ensured the robustness of the antibodies.

Indexed as

B.L.I.ELISASARS-CoV-2

Identifiers

PMID35789908
PMCPMC9232259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.